YY1AP1: A Potential Drug Target and Biomarker for Hepatocellular Carcinoma

Target Name: YY1AP1

NCBI ID: G55249

YY1AP1

YY1AP1: A Potential Drug Target and Biomarker for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a type of liver cancer that is the leading cause of cancer-related deaths worldwide. Currently, there is no effective treatment available for HCC, making it a refractory disease that is often treated with supportive care. Therefore, identifying potential drug targets and biomarkers for HCC is of great interest. One of the potential drug targets that has been identified is YY1AP1 (Hepatocellular carcinoma-associated protein 2).

YY1AP1 is a protein that is expressed in a variety of tissues, including the liver, pancreas, and gastrointestinal tract. It is a member of the YAP/TAZ family of proteins, which are known for their role in cell signaling. YY1AP1 has been shown to be involved in the development and progression of HCC.

Studies have shown that YY1AP1 is overexpressed in HCC tissues and that it is involved in the development of tumor growth, invasiveness, and metastasis. Additionally, YY1AP1 has been shown to be a good biomarker for predicting the prognosis of HCC patients.

Another study has shown that YY1AP1 can be used as a target for small molecule inhibitors. The study found that inhibitors that inhibit YY1AP1 signaling can inhibit the growth and invasion of HCC tumors. This suggests that YY1AP1 may be a promising drug target for HCC.

In addition to its potential as a drug target, YY1AP1 is also a potential biomarker for HCC. Several studies have shown that YY1AP1 is overexpressed in HCC tissues and that it can be used as a biomarker for HCC. For example, one study found that YY1AP1 expression was significantly higher in HCC tissues than in normal tissues.

Another study showed that YY1AP1 was overexpressed in the primary cultures of HCC cancer cells and that inhibition of YY1AP1 signaling led to a decrease in the growth of the cancer cells. This suggests that YY1AP1 may be a promising biomarker for HCC.

In conclusion, YY1AP1 is a protein that has been shown to be involved in the development and progression of HCC. It is also a potential drug target and biomarker for HCC. Further research is needed to fully understand the role of YY1AP1 in HCC and to identify effective small molecule inhibitors that can inhibit its signaling. If successful, YY1AP1 may become a valuable tool for the treatment of HCC.

Protein Name: YY1 Associated Protein 1

Functions: Associates with the INO80 chromatin remodeling complex, which is responsible for transcriptional regulation, DNA repair, and replication (PubMed:27939641). Enhances transcription activation by YY1 (PubMed:14744866). Plays a role in cell cycle regulation (PubMed:17541814, PubMed:27939641)

The "YY1AP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YY1AP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets